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Summary
Background Emergence of artemisinin resistance in southeast Asia poses a serious threat to the global control of 
Plasmodium falciparum malaria. Discovery of the K13 marker has transformed approaches to the monitoring of 
artemisinin resistance, allowing introduction of molecular surveillance in remote areas through analysis of DNA. We 
aimed to assess the spread of artemisinin-resistant P falciparum in Myanmar by determining the relative prevalence 
of P falciparum parasites carrying K13-propeller mutations.
Methods We did this cross-sectional survey at malaria treatment centres at 55 sites in ten administrative regions in 
Myanmar, and in relevant border regions in Thailand and Bangladesh, between January, 2013, and September, 2014. 
K13 sequences from P falciparum infections were obtained mainly by passive case detection. We entered data into two 
geostatistical models to produce predictive maps of the estimated prevalence of mutations of the K13 propeller region 
across Myanmar.
Findings Overall, 371 (39%) of 940 samples carried a K13-propeller mutation. We recorded 26 diﬀ erent mutations, 
including nine mutations not described previously in southeast Asia. In seven (70%) of the ten administrative 
regions of Myanmar, the combined K13-mutation prevalence was more than 20%. Geospatial mapping showed 
that the overall prevalence of K13 mutations exceeded 10% in much of the east and north of the country. In 
Homalin, Sagaing Region, 25 km from the Indian border, 21 (47%) of 45 parasite samples carried K13-propeller 
mutations.
Interpretation Artemisinin resistance extends across much of Myanmar. We recorded P falciparum parasites carrying 
K13-propeller mutations at high prevalence next to the northwestern border with India. Appropriate therapeutic 
regimens should be tested urgently and implemented comprehensively if spread of artemisinin resistance to other 
regions is to be avoided.
Funding Wellcome Trust–Mahidol University–Oxford Tropical Medicine Research Programme and the Bill & Melinda 
Gates Foundation.
Copyright © Tun et al. Open Access article distributed under the terms of CC BY.
Introduction
Artemisinin-based combination treatments are the 
mainstay of treatment for Plasmodium falciparum malaria 
globally, but artemisinin resistance, evidenced by delayed 
parasite clearance after artemisinin treatment, is now 
prevalent across an expanding area of southeast Asia.1–7 
Artemisinin resistance is characterised by reduced 
susceptibility of the ring stage of parasite development8,9 
and is clearly associated with increasing rates of failure 
of artemisinin-based combination treatments in 
Cambodia10–13 and Thailand.14
Mutations that change the primary aminoacid sequence 
of the so-called propeller region of the kelch motif-
containing gene, known as K13, have been identiﬁ ed as a 
key causal determinant of artemisinin resistance in 
southeast Asia,4,15,16 acting through upregulation of 
unfolded protein response pathways.17 Various K13-
propeller mutations have been documented in population 
surveys in the region, and when phenotypes are available 
in numbers suﬃ  cient enough to achieve statistical power, 
the most prevalent mutations are associated with delayed 
parasite clearance after artemisinin treatment4,5,7,18 and 
reduced in-vitro responses.19,20 No frequently occurring 
propeller mutations have yet been identiﬁ ed that are 
associated with normal rates of parasite clearance.4,5,18 
Increasing evidence shows that away from areas of 
artemisinin resistance, mutations in the K13 propeller are 
not present at signiﬁ cant frequencies,5,21–26 and the total 
prevalence of the K13-propeller mutation is less than 5% 
in surveys from a range of transmission settings. 
Discovery of a molecular marker of artemisinin resistance 
before global spread provides a unique opportunity for 
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surveillance to be done in near real-time to support 
containment and elimination strategies.27 WHO have 
incorporated results of K13 marker surveillance into a 
revised deﬁ nition of artemisinin resistance.1
Myanmar stretches from the Bay of Bengal and 
Andaman Sea in the south to the Himalayas in the north, 
and therefore provides the only route for drug-resistant 
falciparum malaria to spread contiguously from southeast 
Asia to the Indian subcontinent,28 a path followed by 
resistance to chloroquine and probably pyrimethamine 
nearly half a century ago.29 Artemisinin resistance in 
P falciparum has been present at the Myanmar–Thailand 
border for several years,6,30 and slow parasite clearance 
after artemisinin-based combination treatments has also 
been reported in southeastern Myanmar.31,32 In 2011–12 in 
Shwe Kyin, Bago Region, roughly 15% of patients had 
delayed parasite clearance (a clearance half-life >5 h), and 
a quarter had mutations in the propeller region of the K13 
protein.5 Before this study, the prevalence of artemisinin-
resistant parasites in other parts of Myanmar had not 
been reported. Here, we present a detailed molecular 
survey of K13 based on P falciparum ﬁ eld isolates obtained 
from patients in Myanmar and neighbouring regions. 
Methods
Study design and patients
We obtained samples for K13 genotyping from 
symptomatic patients presenting with fever to malaria 
treatment centres at 55 sites in ten administrative 
regions in Myanmar, and two cross-border areas in 
Thailand and Bangladesh, between August, 2013, and 
September, 2014. Patients had falciparum malaria 
conﬁ rmed by blood smear or rapid diagnostic test. For 
patients enrolled in prospective clinical studies, either 
whole blood samples or dried blood spots on ﬁ lter paper 
were collected after fully informed consent was 
obtained. In a small subset of these patients, both the 
screening rapid diagnostic test and the whole blood 
sample were processed to check for concordance. For 
patients being managed with routine care, used rapid 
diagnostic tests were retained anonymously for later 
extraction of plasmodium DNA. Additionally, whole 
blood samples were collected between January and 
December, 2013, as part of ongoing epidemiological 
studies in villages and camps on either side of the 
Myanmar–Thailand border (in Tak province and Kayin 
State) and for hospital-based studies done between May 
and September, 2014, in Ramu, Bangladesh. This 
method led to unequal distributions of sample types 
and patient characteristics (clinical severity, age, sex, 
and pregnant state) across the various sites. However 
these factors were thought unlikely to signiﬁ cantly 
aﬀ ect the overall prevalence of K13-marker mutations at 
each site. In accordance with therapeutic eﬃ  cacy 
studies,33 we planned to obtain at least 50 sequences in 
each administrative division, although we anticipated 
that this might not be achieved for operational reasons 
and possible failure to obtain the necessary K13 
sequence in a speciﬁ c sample.
Ethics review and approval was obtained from the 
Faculty of Tropical Medicine, Mahidol University 
(Thailand); Department of Medical Research, Ministry of 
Health (Myanmar); The Defence Services Medical Ethics 
Committee (Myanmar); and Oxford Tropical Research 
Ethics Committee (UK). Samples from within Thailand 
and Bangladesh were obtained as part of prospective 
clinical studies covered by existing ethical approvals.
Procedures
DNA was extracted from dried blood spots, completed 
rapid diagnostic test strips (both stored desiccated at 
room temperature), and frozen whole blood samples, by 
standard methods.5 Relevant primers derived from the 
K13 gene sequence were used to amplify the full kelch13 
open-reading frame with use of a nested PCR protocol5 to 
describe the complete sequence from aminoacid 210 
onwards (the conserved part of the protein). We regarded 
heterozygous results as mutations.
Geospatial mapping
For the purpose of predictive geospatial mapping, we 
calculated the total proportion of samples in each location 
with a non-synonymous mutation after aminoacid 
position 440 of the K13 gene. These data, in addition to 
the total number of samples and geographical information 
system coordinates for each sampling site, were entered 
into a geostatistical model, producing a predictive map of 
estimated mutation prevalence on a 5 × 5 km grid in 
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Figure 1: Location of sampling sites, sample sizes, and administrative states and regions of Myanmar, and a 
relief map of southeast Asia
Red circles show numbers of patients in each region.
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Myanmar. To reduce model uncertainty and achieve a 
robust estimate of the prevalence of the K13 mutation, we 
used two alternative geostatistical modelling approaches. 
The ﬁ rst approach involved use of a regression model 
implemented within a Bayesian framework, producing a 
posterior distribution of prevalences summarised by the 
median to create a single continuous surface as described 
previously (appendix).34 Second, we applied the well-
established spatial statistical interpolation method of 
ordinary kriging.35 With both models we generated a 
corresponding uncertainty map to show the conﬁ dence 
associated with the predictions across the map domain. 
In the Bayesian model, this prediction error was 
represented by a corresponding SD surface, whereas in 
the kriging model it was shown by the kriging variance. 
With the kriging approach, we also used a variogram to 
describe the strength of spatial dependence shown in the 
data (appendix).
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the location of sampling sites, sample 
sizes, and administrative states and regions of Myanmar. 
Of 2378 samples tested, 940 (40%) samples produced 
clear sequences covering aminoacids 210–726 of the K13 
gene. The overall extraction–sequencing success rates 
were 97% for whole blood, 84% for dried blood spots, and 
26% for rapid diagnostic tests. We did not screen samples 
with PCR before attempting to sequence K13. 11 of 
12 samples sequenced from both rapid diagnostic tests 
and whole blood showed concordant sequences, with the 
remaining sample failing to produce a sequence from 
the diagnostic test. Only ﬁ ve mixed genotypes were 
apparent in sequencing reads.
We identiﬁ ed 29 diﬀ erent mutations after aminoacid 
210, of which 26 (90%) were after aminoacid 440 
(appendix). 371 (39%) isolates had a propeller-domain 
mutation (table). Consistent with previous reports,4,5 
these mutations were concentrated within propeller 
blades 1–4 (ﬁ gure 2). 17 isolates had an E252Q mutation 
in the so-called stem section of the K13 protein; one (2%) 
from Bago Region, 11 (4%) from Kayin State, and ﬁ ve 
(3%) from Tak Province. No sample had more than one 
mutation in these conserved domains of the protein.
Several mutations seemed to be concentrated in 
speciﬁ c regions of Myanmar (ﬁ gure 3). F446I was 
identiﬁ ed in 80 samples across six states or regions with 
several regions in Upper Myanmar showing prevalences 
in excess of 10%; 21 (47%) of 45 samples obtained in 
Homalin, Sagaing Region (25 km from the India border) 
had K13-propeller mutations (mostly the F446I 
mutation). The P574L mutation was also widely 
identiﬁ ed, being present in 41 samples across seven 
states or regions, whereas the A676D mutation was 
identiﬁ ed in three northern states or regions only 
(ﬁ gure 3). The C580Y mutation, identiﬁ ed at high 
prevalence in western Cambodia,4 was conﬁ ned to Kayin 
state, and was also present at high prevalence across the 
adjacent western part of Tak province in Thailand 
(ﬁ gure 3). Notably, the M476I mutation, shown to 
develop after prolonged in-vitro artemisinin selection,4 
was identiﬁ ed in 18 isolates.
Roughly two-thirds of the identiﬁ ed K13 mutations had 
been described previously in Myanmar or at the 
Myanmar–Thailand border,5,18,36 and a further subset of 
these had also been reported in Cambodia.4,5 These 
previously identiﬁ ed mutations tended to have higher 
See Online for appendix
Total 
samples
Samples with 
propeller 
mutation*
Proportion (%)
Myanmar
Bago 52 0 0 (0–6·9)
Chin 62 2 3·2 (0·9–11)
Kachin 70 26 37·1 (26·8–48·9)
Kayah 2 2 100 (34·2–100)
Kayin 288 137 47·6 (41·9–53·3)
Mandalay 181 43 23·8 (18·1–30·5)
Mon 8 3 37·5 (13·7–69·4)
Rakhine 29 2 6·9 (1·9–22)
Sagaing 46 21 45·7 (32·2–59·8)
Shan 21 14 66·7 (45·4–82·8)
Bangladesh
Chittagong 25 0 0 (0–13·3)
Thailand
Tak 156 121 77·6 (70·4–83·4)
Total 940 371 39·5 (36·4–42·6)
Data in parentheses are 95% CI. We calculated conﬁ dence intervals with the 
Wilson Test (without continuity correction). *After aminoacid 440.
Table: Number of samples per region and proportion with mutations in 
the propeller domain of K13
Figure 2: Primary aminoacid positions of K13 mutations identiﬁ ed in Myanmar and border regions
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prevalences than those that were unique to Myanmar, 
none of which was identiﬁ ed in more than ten isolates 
(appendix). We identiﬁ ed three rare (three samples or 
less) synonymous mutations in the sequence after 
aminoacid 210 in the set of 759 samples from within 
Myanmar. Calculation of intraspeciﬁ c evolutionary 
coeﬃ  cients (with Jukes-Cantor correction) produced 
values of 0·0123 for dS and of 0·0136 for dN. Inference 
of selective forces from the resulting intraspeciﬁ c dN to 
dS ratio of 1·10 is challenging, but the ﬁ ndings are 
compatible with strong positive selection.37
We calculated the total prevalence of K13-propeller 
mutations for each administrative region (table) and site 
as the proportion of samples with any mutation after 
aminoacid 440. We entered these point metrics into two 
independent geospatial models to obtain continuous 
prevalence maps for Myanmar (ﬁ gure 4). Both maps 
showed a large area of fairly high mutation prevalence 
(substantially more than 10%) extending from the 
southeast to the north of the country (ﬁ gure 4). Much of 
Lower Myanmar, and Chin and Rakhine states in the 
west, had a very low prevalence of K13 mutations, a 
Figure 3: Local prevalence of individual K13 mutations by administrative state or region in Myanmar
Only mutations found in at least nine isolates, or at lea st three states or regions, are shown.
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ﬁ nding consistent with the absence of K13 mutant 
parasites in adjacent Bangladesh (ﬁ gure 4).
Discussion
Our ﬁ ndings provide strong evidence that artemisinin-
resistant falciparum malaria extends across much of 
Upper Myanmar, including regions close to the Indian 
border in the northwest. By comparison, Lower Myanmar 
and the mountainous western states (Rakhine and Chin) 
currently have a relatively low prevalence of K13 
mutations, and there is no evidence of spread into 
southeastern Bangladesh. There is also no evidence that 
artemisinin resistance has reached India; however, few 
data are available.38,39 An independent study examining 
samples from 91 patients in Kayin state in east Myanmar 
and Chin state in the west likewise reported a range of 
K13-propeller mutations, with a higher prevalence in the 
eastern region and relatively few K13-mutant parasites at 
the western border with Bangladesh.36
Artemisinin resistance became established in western 
Cambodia more than a decade ago.4 Studies of population 
genetics have described P falciparum founder populations 
that share an underlying predisposed genetic 
background40 rising to fairly high levels; each population 
is linked to speciﬁ c K13 mutations41 and has high levels of 
artemisinin resistance both in vivo and in vitro.19 Seven 
individual mutations seem to have arisen independently 
on more than one occasion in diﬀ erent locations; these 
mutations include C580Y, which is reaching ﬁ xation in 
various regions. In the present study, C580Y parasites 
were only located at the Myanmar–Thailand border, 
although this lineage seems to be separate to that in 
Cambodia.18 Few of the K13 mutants currently in 
Myanmar have been reported at high prevalence in 
Cambodia; furthermore, the Myanmar mutations seem 
to be clustered towards the ﬁ rst kelch domain (aminoacids 
441–475) with one mutant in the conserved stem of the 
protein (E252Q) also reaching signiﬁ cant frequencies in 
southeast Myanmar. In the north of Myanmar, including 
sites very close to the Indian border, prevalence of the 
F446I mutation is high. Why there are diﬀ erent sets of 
mutations in diﬀ erent locations is not yet clear, but one 
possible explanation is that Myanmar is at an earlier stage 
of an evolutionary process than Cambodia. The prevalent 
mutations in Myanmar might provide reduced levels of 
artemisinin resistance (although the widespread P574L 
mutation seems to be associated with parasite clearance 
that is at least as slow as C580Y5,18) or might bring ﬁ tness 
costs, so that they are outcompeted by ﬁ tter alternatives 
such as C580Y over time. Alternatively there might be 
distinctive selective forces resulting from diﬀ erent 
antimalarial use, host genetics, or mosquito biology that 
promote diﬀ erential sets of mutations in the two regions. 
Further studies of parasite ﬁ tness and in-vitro drug 
sensitivity are likely to shed light on these questions.
This study shows that valuable real-time molecular 
epidemiological surveillance and monitoring can be 
done with used rapid diagnostic tests (and with dried 
blood spots) if there is a system to obtain these tests and 
send them to a reference laboratory. The two geospatial 
models described provide consistent and informative up-
to-date knowledge of the extent of resistance to 
artemisinins in Myanmar and could be used to guide and 
prioritise interventions. Additional data are needed to 
reduce the uncertainty of the present estimates of 
resistance in speciﬁ c locations, potentially guided by 
surveillance modelling methods.
The global spread of chloroquine resistance resulted in 
the loss of millions of lives in Africa and, clearly, 
Myanmar is an important part of the frontline in the 
battle to contain artemisinin resistance. These data 
emphasise the concern that artemisinin resistance could 
follow historical paths of the spread of antimalarial drug 
resistance from southeast Asia, via Myanmar, through 
India to Africa.42 Moreover, substantial increases in 
international travel and migration could promote direct 
spread of artemisinin resistance (so-called jumping).43 
Local emergence of resistance parasite is an alternative 
scenario (so-called popping).
Myanmar has substantially more malaria than any 
other country in southeast Asia,44 so aside from the wide 
implications, artemisinin resistance could reverse recent 
downward trends in morbidity and mortality from 
malaria in the country. Knowledge of the level of K13-
propeller mutations provides a snapshot of the extent of 
artemisinin resistance, but does not in itself provide 
direct information about the eﬀ ectiveness of Myanmar’s 
present ﬁ rst-line artemisinin-based combination treat-
ment, artemether–lumefantrine. If, for example, the 
artemisinin resistance reported here results from early 
wide-scale availability of artemisinin monotherapy, the 
lumefantrine component could be suﬃ  ciently eﬀ ective 
for the combination to retain high eﬀ ectiveness in at 
least some regions of Myanmar. However, declining 
Figure 4: Geographical extent of predicted artemisinin resistance as determined by the prevalence of K13 
propeller mutations (>440 aminoacids) visualised by approaches using a Bayesian model (A, with 
uncertainty shown in B) and kriging interpolation (C, with uncertainty shown in D)
In the main prevalence maps, colour shows total prevalence of relevant K13 mutations (median in A and mean in 
C). In the uncertainty maps, orange and red areas show the greatest uncertainty in Shan State (in the east) and the 
southern peninsula. In A the colour of the circles is proportional to the recorded K13-mutation prevalence at a 
particular site and the radius of the circle is proportional to the sample size of the study.
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eﬀ ectiveness of artemisinin-based combination treat-
ments, representing a combination of artemisinin 
resistance and failing partner drug (meﬂ oquine), is 
already a substantial problem on the eastern Myanmar 
border14 and, in view of the cross-resistance between 
meﬂ oquine and lumefantrine, eﬀ ectiveness in that 
region is probably poor. In other regions where K13-
mutant parasites are prevalent, prediction of eﬀ ectiveness 
is diﬃ  cult, and therapeutic eﬃ  cacy studies—the 
deﬁ nitive method for identiﬁ cation of whether a 
combination is beginning to fail—are urgently needed, 
with a focus on the areas of emerging artemisinin 
resistance evident in this survey. Measurement of pfmdr1 
copy number in these samples would also be useful in 
this respect.
Artemisinin resistance has not been contained. Present 
artemisinin-based combination treatments are failing in 
areas aﬀ ected by artemisinin resistance and there is a real 
threat that the incidence of P falciparum will begin to rise 
again, thus confounding regional aspirations to eliminate 
malaria (panel). Even low numbers of recrudescences fuel 
the emergence and spread of resistance to the partner 
drug (which is exposed to a higher parasite burden 
because of reduced parasite killing by the artemisinin 
derivative), substantially shortening the lifetime of any 
artemisinin-based combination treatment.45 Switching to 
an alternative partner (such as piperaquine) successfully, 
but only temporarily, improved the eﬀ ectiveness of 
artemisinin-based combination treatments in western 
Cambodia.13 These considerations suggest that malaria 
treatment needs to be revised. Use of regimens of more 
than 3 days’ duration, or containing more than one partner 
drug, will become necessary across an expanding area of 
southeast Asia. The pace at which the geographical extent 
of artemisinin resistance is spreading is faster than the 
rate at which control and elimination measures are being 
developed and instituted, or new drugs being introduced. 
A vigorous international eﬀ ort to contain this enormous 
threat is needed.
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Panel: Research in context
Systematic review
We searched PubMed from January, 2000, to January, 2015, 
with the terms “K13 or kelch” and “falciparum” and identiﬁ ed 
18 papers. 13 papers, all of which were done between July, 
2014, and January, 2015, and undertaken on the basis of the 
discovery of the K13 marker by Ariey and colleagues,4 reported 
molecular surveys of the K13 marker in ﬁ eld isolates. 
Mutations in the propeller region of the K13 protein (which 
consists of six kelch domains) cause artemisinin resistance in 
the ring stage of the parasite,16 although background parasite 
genetic traits are also important.16,40 Findings from the 
Tracking Resistance to Artemisinin Collaboration study5 
showed that artemisinin resistance was present in much of 
the lower Mekong region and that Myanmar spanned the 
divide between resistant and sensitive regions. The ability to 
establish the parasite’s K13 sequence from blood samples 
stored at room temperature (as dried blood spots or discarded 
rapid diagnostic tests) provided an opportunity to assess the 
degree of artemisinin resistance in fairly remote areas.27
Interpretation
The long-term eﬀ ectiveness of the present ﬁ rst-line 
treatment for falciparum malaria—artemisinin-based 
combination treatment—is dependent on the ring-stage 
killing action of artemisinins. Once this action is lost, 
artemisinins exert less antimalarial eﬀ ect and resistance to 
the slower-acting partner drug is bound to develop over time. 
Our study shows that artemisinin resistance extends over 
more of southeast Asia than had previously been known, and 
is now present close to the border with India. This ﬁ nding 
expands the area in which containment and elimination are 
needed to prevent the possibility of global spread of 
artemisinin resistance.
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